Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Voyager Therapeutics (VYGR) Common Equity (2016 - 2025)

Voyager Therapeutics (VYGR) has disclosed Common Equity for 11 consecutive years, with $196.1 million as the latest value for Q4 2025.

  • Quarterly Common Equity fell 34.59% to $196.1 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $196.1 million through Dec 2025, down 34.59% year-over-year, with the annual reading at $196.1 million for FY2025, 34.59% down from the prior year.
  • Common Equity hit $196.1 million in Q4 2025 for Voyager Therapeutics, down from $219.8 million in the prior quarter.
  • In the past five years, Common Equity ranged from a high of $340.9 million in Q1 2024 to a low of $59.0 million in Q4 2022.
  • Historically, Common Equity has averaged $188.6 million across 5 years, with a median of $197.6 million in 2023.
  • Biggest five-year swings in Common Equity: plummeted 47.41% in 2021 and later skyrocketed 300.41% in 2023.
  • Year by year, Common Equity stood at $95.1 million in 2021, then crashed by 37.91% to $59.0 million in 2022, then surged by 300.41% to $236.3 million in 2023, then grew by 26.84% to $299.8 million in 2024, then tumbled by 34.59% to $196.1 million in 2025.
  • Business Quant data shows Common Equity for VYGR at $196.1 million in Q4 2025, $219.8 million in Q3 2025, and $243.9 million in Q2 2025.